Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for March 2012
March 1, 2012
- AltheRx Presents Positive Phase II Results of Solabegron in Overactive Bladder at the European Association of Urology Congress
- QLT Announces Positive Preliminary Results From Phase 1b Trial of QLT091001 in Subjects With Retinitis Pigmentosa Due to RPE65 and LRAT Mutations
- Study Published in Molecular Therapy Shows that Immune Response to FANG Personalized Cancer Therapeutic Correlates with Prolonged Survival in Patients with Advanced Stage Cancer
- VAYA Pharma: New Research Highlights the Importance of Lipids for Memory Function
- Transgenomic's Proprietary Clopidogrel (Plavix) Response Panel Includes Both Genetic Markers Demonstrated to Be Significant in Third Independent Study
- U.S. Food and Drug Administration Extends Action Date for ELIQUIS (apixaban) by Three Months
- Solving Mystery of How Sulfa Drugs Kill Bacteria Yields 21st Century Drug Development Target
- Diabetes Research Institute Develops Revolutionary Oxygen-Generating Biomaterial to Enhance Islet Survival
March 2, 2012
- Genentech's Actemra Monotherapy Showed Superior Improvement in Rheumatoid Arthritis Signs and Symptoms Versus Adalimumab Monotherapy
- Roche's Roactemra Monotherapy Showed Superior Improvement in Rheumatoid Arthritis Signs and Symptoms Versus Adalimumab Monotherapy
- Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control
March 5, 2012
- Inovio Therapeutic Vaccine for Head & Neck and Other HPV-Related Cancers Induces Robust T-Cell Immune Response in Mice
- Baxter Presents Long-Term Data on HyQ During AAAAI Annual Meeting
- Merck's Investigational Allergy Immunotherapy Tablet (AIT) Significantly Reduced the Combination of Ragweed Allergy Symptoms and Medication Use in Phase III Trial
- Zalicus Successfully Completes Phase 1 Clinical Study with Reformulated Z160
- QNASL Phase III Data Indicate Investigational Therapy with New Mode of Delivery has Positive Safety and Effective Profile in Treatment of Seasonal and Perennial Allergic Rhinitis
March 6, 2012
- Phase 3 Long-Term Safety Trial Results of Lubiprostone in Patients with Irritable Bowel Syndrome with Constipation was Recently Published in Alimentary Pharmacology and Therapeutics
- AMAG Pharmaceuticals, Inc. to Host Conference Call on March 7, 2012 at 4:30 p.m. ET to Discuss Feraheme Clinical Trial Results
- AMAG Pharmaceuticals, Inc. to Host Conference Call on March 7, 2012 at 4:30 p.m. ET to Discuss Feraheme Clinical Trial Results
- Gilead Sciences Quad Study 102 Results Conference Call on Wednesday, March 7, 2012
- Data from Phase 2 Study of an INCIVEK Combination Regimen Showed 74% of People Co-Infected with Hepatitis C and HIV Had Undetectable Hepatitis C Virus 12 Weeks After Treatment Ended (SVR12)
March 7, 2012
- BioSante's Prostate Cancer Vaccine Resulted in Stable Disease in Over 50% of Patients in Newly Published Study
- Forest Laboratories, Inc. and Pierre Fabre Medicament Announce Positive Phase III Results For Levomilnacipran in Patients with Major Depressive Disorder
- Analysis Finds Bioavailability of IgG is Consistent, Regardless of Formulation
- Results from Investigational Studies with VICTRELIS (boceprevir) Presented at the Conference on Retroviruses and Opportunistic Infections to Understand Potential Use in Patients Coinfected with Chronic Hepatitis C and HIV-1
- CSL Behring Study Confirms Early Treatment with Berinert Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
- Survey Reveals a Majority of Cancer Patients, Survivors Are Unaware of Higher Risk for Developing Deep-Vein Thrombosis and Pulmonary Embolism
- New Transplant Method May Allow Kidney Recipients to Live Life Free of Anti-Rejection Medication
- GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI)
- Gilead's Quad Single Tablet Regimen for HIV Non-Inferior to Atripla in Pivotal Phase 3 Study
- AMAG Pharmaceuticals Announces Preliminary Results from its Phase III Study Evaluating Feraheme Compared to IV Iron Sucrose in Patients with Iron Deficiency Anemia
- MRI Contrast Agents Go Head-to-Head: Researchers Find Greater Morphologic Information and Lesion Enhancement with Bracco's MultiHance® (gadobenate dimeglumine) Injection, 529 mg/mL When Compared to Gadavist (gadobutrol injection)
- New Data Confirm Gilead's HIV Prevention Pill Fails Says AHF
- Data in NEJM shows Novartis drug Signifor is first therapy to provide rapid, durable benefit for Cushing's disease patients in Phase III study
- New England Journal of Medicine Publishes Data from Phase 2 Study of Asfotase Alfa in Life-Threatening Hypophosphatasia
- New England Journal of Medicine Publishes Data from Phase 2 Study of Asfotase Alfa in Life-Threatening Hypophosphatasia
March 8, 2012
- Circassia's Ragweed Allergy Therapy Achieves Positive Phase II Clinical Results
- KALBITOR® (ecallantide) Data Presented at American Academy of Allergy, Asthma and Immunology Annual Meeting
- Cytheris announces results of phase II study indicating that recombinant Interleukin-7 (CYT107) expands CD4 T-cells in gut mucosa of chronically HIV infected immunological non-responder patients
- Apogenix Announces that APG101 Meets Primary Endpoint in a Controlled Phase II Trial with Glioblastoma Patients
- Study Unblinded: ZYTIGA (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer
- New Treatment Presented for Chronic Diarrhea in HIV/AIDS Patients
- Sangamo Presents New Clinical Data at CROI 2012 Demonstrating Persistent Positive Effects of ZFN Therapeutic for "Functional Cure" of HIV/AIDS
- Cannabis Science Reports Cancer Tumors Continues to Shrink and Die as Apparent Pieces of the Dying Cancer Tumors Begin to Fall off as Evidenced in Newest Photos of the 3rd Squamous Cell Carcinoma Patient
- Data Show Gilead's Quad Regimen for HIV Non-Inferior to Protease-Based Regimen at 48 Weeks in Second Pivotal Phase 3 Study
March 9, 2012
March 12, 2012
- New Publication Presents Comparative Efficacy Data for Abbott's Zemplar (paricalcitol) in Treating Secondary Hyperparathyroidism in Hemodialysis Patients
- Inviragen Hand, Foot and Mouth Disease Vaccine Generates Immune Responses in 100% of Study Participants
- Tranzyme Pharma and Norgine Announce Top-Line Data From ULISES 007, the First of Two Phase 3 Pivotal Trials
- ImmunoCellular Therapeutics Reports Manufacturing Process Data for ICT-107
- Pfizer's Prevnar 13 Shown to be Immunogenic in Older Children and Adolescents
- Parkinson's Disease Stopped in Animal Model
- Metabolic Solutions Development Company Presents Case Study: A New Approach to Insulin Sensitizers During Phacilitate-Metabolic Leaders Forum 2012
- Upsher-Smith Presents Data Highlighting Topiramate Extended-Release Formulation at 100th Annual APhA Meeting
- PointCross Life Sciences Announces DSIMS: Drug Safety Information Management Suite
March 13, 2012
- Immunogenicity and Favorable Tolerability Observed in Phase II Clinical Trial for H5N1 Influenza Vaccine ASP7373
- Inovio Pharmaceuticals' PENNVAX-B HIV Vaccine Demonstrates Strong T-Cell Immune Responses in Therapeutic Vaccine Trial
- Genome Sequencing Initiative Links Altered Gene to Age-Related Neuroblastoma Risk
March 14, 2012
- RBCC: Promising New Parkinson's Therapies May Also Treat Brain Injuries
- Omeros' Ophthalmology Product OMS302 Achieves Primary and Secondary Endpoints in Phase 3 Clinical Trial
- Deaths From Gastroenteritis Double
- New England Journal of Medicine Article Reviews the Benefits of Ingenol Mebutate in Field Treatment of Actinic Keratoses
- Landmark Study Finds Expensive Catheter Procedure to Close Hole in Heart No More Effective Than Medical Therapy to Prevent Strokes
- Nile Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
March 15, 2012
- Phase III Study of Teva's Oral Laquinimod Published in the New England Journal of Medicine Demonstrates Clinical Benefits for Multiple Sclerosis Patients
- DATATRAK International, Inc. Announces Fourth Quarter and Full Year Results for 2011
- UCB and Domainex Collaboration Provides Valuable Information on Cancer Drug Target
- VAP Cholesterol Test Helps Researchers Study Dyslipidemia, Assess Effectiveness of New Anti-flushing Agent
March 16, 2012
- Embera NeuroTherapeutics and Collaborators Publish Paper in Psychopharmacology Supporting Its Novel Drug Combination, EMB-001, for Smoking Cessation
- Obesity Raises Death Risk Tied To Sleeping Pills
- New Clues For the Cause of Alzheimer's Disease
March 19, 2012
- Provectus Announces Top Line Phase 2 Data For PH-10 in Its First Randomized Controlled Psoriasis Study
- Presentation of Highlight Results from Phase 3 Trial of TAK-085 in Japan for the Treatment of Hyperlipidemia at the 76th Annual Scientific Meeting of the Japanese Circulation Society
March 20, 2012
- Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug
- BioSante Pharmaceuticals Announces Positive Pill-Plus Data Presentation
- Obagi Medical Products Presents Study Results at American Academy of Dermatology
- Aerpio Announces Positive Phase 1 Data on First-in-class Tie2 Activator, AKB-9778, in Development for Diabetic Macular Edema
- Trianz Solutions Releases a White Paper Entitled ?Switching EDC Platforms to Rescue In-flight Clinical Trials?
March 21, 2012
- Fraunhofer USA CMB Confirms Interim Results for Its Plant-Produced H1N1 Influenza Vaccine
- Researchers Discover Drug Target for Stimulating Recovery From Stroke
- VBL Therapeutics Presents Positive Phase 2 Data for VB-201 in Psoriasis and Atherosclerosis at the Late-Breaking Abstract Session of the American Academy of Dermatology 70th Annual Meeting
March 22, 2012
- Regeneron Announces Data Publication and Presentations with Potential First-in-Class Lipid-Lowering PCSK9 Antibody
- POZEN Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of PA32540
- Added Benefit of Fixed Combination Aliskiren/Amlodipine Is Not Proven
March 23, 2012
- GSK and Theravance Announce Completion of the Relovair Registrational Programme and Topline Results From Relovair Vs. Advair Phase III Studies in COPD
- Experts Challenge FDA Over Approval for New Dose of Alzheimer?s Drug
- Mechanism of Action Data On PV-10 Demonstrates Therapy Induces Immunologic Response
March 26, 2012
- Landmark Analysis of Year Two Data From PLATINUM Workhorse Trial Demonstrates Superior Efficacy of PROMUS Element Platinum Chromium Stent Compared to PROMUS (Xience V) Stent
- American College of Cardiology Poster Abstract Shows Standard Lipid Profile Inaccurate for LDL Cholesterol Below 70 mg/dL
- The Lancet Infectious Diseases Publishes Phase 3 Study Results Confirming Superior Rate of Sustained Clinical Response of DIFICID(R) (fidaxomicin) Tablets Compared to Oral Vancomycin in Adult Patients with Clostridium difficile Infection (CDI)
- New Data Suggests Results of PLATO Genetic Sub-Study Outcomes for BRILINTA® (Ticagrelor) Not Driven by Poor Metabolizers of Clopidogrel
- Amgen's PCSK9 Inhibitor Reduced LDL Cholesterol up to 81 Percent in Phase 1b Study
- Medtronic Resolute Drug-Eluting Stent Delivers Durable Clinical Outcomes Through Two Years in Major Studies
- Theravalues: Extensive Clinical Trials Affirms the Benefits of Theracurmin on Diastolic Function in Hypertensive Patients
- New Data Suggests BRILINTA (ticagrelor) Reduced First and Recurrent Cardiovascular and Ischemic Events
- In TRA-2P Study, Adding Merck's Vorapaxar to Standard of Care Significantly Reduced the Risk of Cardiovascular Events
- Infusion of Drug Into the Coronary Artery May Help Reduce Size of Heart Damage in Patients With Heart Attack
- XARELTO (rivaroxaban) Demonstrates Comparable Efficacy to Standard of Care for the Treatment and Secondary Prevention of Venous Blood Clots in Patients with Symptomatic Pulmonary Embolism in Pivotal Phase 3 Study
- Esperion Announces Positive Phase 2 Clinical Trial Results for ETC-1002
- Intralesional PV-10 Treatment Leads to the Induction of Anti-Tumor Immunity
- Gencaro Norepinephrine Lowering Likely Contributes to Its Effect in Atrial Fibrillation Prevention
- Sanofi and Regeneron Report Phase 2 Data for Potential First-in-Class Lipid-Lowering PCSK9 Antibody
- STENTYS Self-Apposing technology supported by breaking new scientific evidence
- Crestor Delivers Latest LDL-C Targets in High-Risk Patients at Lower Doses than Other Statins
- Analysis of Two Randomized Clinical Trials Identify No Cases of Longitudinal Stent Deformation With Boston Scientific Platinum Chromium Stents
- Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia
- Seattle Genetics Announces Pivotal ADCETRIS (Brentuximab Vedotin) Hodgkin Lymphoma Study Published in Journal of Clinical Oncology
March 27, 2012
- Rexahn Pharmaceuticals to Present Data on Novel Anti-Cancer Small Molecule RX-3117 at AACR 103rd Annual Meeting
- Vaccine Applications of iBio's Proprietary Lichenase Technology Reported at International Conference
- LabConnect Launches Its Global Sample Tracking Solution
- Data Presented at ACC.12 Demonstrate that OrbusNeich's Genous Stent Is Feasible and Safe in STEMI Patients
- New Data Updating Overall Survival Rate in Olaparib Study
March 28, 2012
- Allergan Announces Positive Top-Line Results from Phase III Botox Overactive Bladder Program
- Targacept Announces Top-Line Results from Two Exploratory Phase 2 Studies of TC-6987
- Advaxis Announces Abstracts Accepted for Poster Presentation at AACR Annual Meeting 2012
- Researchers Identify New Regulator in Allergic Diseases
- Neuralstem ALS Stem Cell Trial Interim Results Reported in the Journal, STEM CELLS
- Navidea Biopharmaceuticals Announces Presentation of Lymphoseek Phase 3 Data at Society of Surgical Oncology Meeting
- Research Institute Brainclinics: Doubling of Neurofeedback Efficacy in ADHD Treatment
- Amsterdam Molecular Therapeutics Publishes Positive Data from Glybera 14 Week Study
- Findings Confirm Benefits of Albumin in Treating Cirrhosis Patients Undergoing Large-Volume Paracentesis
- Dynavax Reports Final Phase 3 Data for Heplisav in CKD Patients and New Data From Booster Trial in Hemodialysis Patients
- Nile Therapeutics Announces Positive Clinical Trial Results Evaluating the Subcutaneous Infusion of Cenderitide
- Amgen Announces Phase 2 Study Results for Brodalumab in Moderate to Severe Plaque Psoriasis Published in the New England Journal of Medicine
- Lilly's Anti-IL-17 Monoclonal Antibody, Ixekizumab, Met Primary Endpoint in Phase II Study in Patients With Chronic Plaque Psoriasis
March 29, 2012
- Lilly (Eli) & Company - Ixekizumab Ph2 Psoriasis Data in NEJM
- ArQule Announces Presentations at AACR 102nd Annual Meeting
- Groundbreaking Treatment Cures Hypertension, Atherosclerosis and High Cholesterol
- One Year Data Provide Evidence of Effectiveness and Tolerability of REPLAGAL (agalsidase alfa) in Fabry Patients
- KYNAMRO (mipomersen sodium) Data Presented at XVI International Symposium on Atherosclerosis
- Asfotase Alfa Significantly Decreased TNSALP Substrates and Improved 6-Minute Walk Test Results in Adolescents and Adults with Hypophosphatasia (HPP)
- Scripps Research Institute Scientists Create Compounds that Dramatically Alter Biological Clock and Lead to Weight Loss
- Research Finds Overdose Deaths Occur When Changing Opioids
- Sinovac's EV71 Vaccine Phase I Clinical Data for the Prevention of Epidemic Hand, Foot, Mouth Disease Published in Vaccine
- Astex Pharmaceuticals to Present at AACR Annual Meeting
- Oncolytics Biotech Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
- Tau Therapeutics LLC to Present Posters at AACR on T-Type Calcium Channel Inhibitors and Interlaced Therapy
March 30, 2012
- ImmunoGen, Inc. Announces Positive Results in Trastuzumab Emtansine (T-DM1) EMILIA Phase III Trial
- MOLOGEN AG: Treatment with renal cancer therapy MGN1601 generates clear survival benefit for patients
- Shire Announces Top-line Results of the PREVENT2 Trial
- Genentech's Trastuzumab Emtansine (T-DM1) Showed Positive Phase III Results In HER2-Positive Metastatic Breast Cancer
- Transgenomic, Inc. Announces Presentation of Results from 448-Gene NuclearMitome Test in 78 Patients at the 2012 Annual Meeting of the American College of Medical Genetics
